The narcolepsy treatment market is projected to grow from USD 5,301.6 million in 2024 to USD 8,718.3 million by 2034, at a ...

Agonists of gamma-aminobutyric acid (GABA B) receptors, which are indicated for the treatment of narcolepsy, currently represent more than $1.7 billion in annual sales in the United States.

People who live with narcolepsy — about one out of every 2,000 Americans — don’t have many options when it comes to treatment. The milder form of narcolepsy includes symptoms of excessive ...

The FDA has expanded the approval of Lumryz (sodium oxybate) extended-release oral suspension to include treatment of pediatric narcolepsy.

Various medications that treat narcolepsy are available, and treatment plans can vary based on individual symptoms and other ...

Neuraxpharm Group (Neuraxpharm), a leading European specialty pharmaceutical company focused on the treatment of central nervous system (CNS) disorders, announces today that it has acquired at the end ...

Neuraxpharm Group (Neuraxpharm), a leading European specialty pharmaceutical company focused on the treatment of central nervous system (CNS) disorders, announces today that it has acquired at the end ...

Considering taking supplements to treat narcolepsy? Below is a list of common natural remedies used to treat or reduce the symptoms of narcolepsy. Follow the links to read common uses, side ...

It was a huge relief to be diagnosed with narcolepsy, because I was able to finally say this is the problem. And this is what I need to resolve the problem. Treatment has been life-changing.

Among the myriad drugmakers laying out their plans for the future at this year’s J.P. Morgan Healthcare Conference, Takeda ...

Preliminary Fourth Quarter and Full Year 2024 Net Product Revenue (Unaudited) Based on preliminary unaudited financial information, Axsome expects total product revenue to be approximately $118.3 ...